Date: 2016-06-22
Type of information: Licensing agreement
Compound: Nanofitin®-conjugated biotherapeutics
Company: Affilogic (France) Sanofi (France)
Therapeutic area:
Type agreement: R&D licensing
Action mechanism: protein. Nanofitins® are small affinity proteins that can be easily conjugated to other moieties (small molecule, biologics, nanoparticles) by genetic fusion or standard chemistry (regio-selective conjugation). This enables to consider a Nanofitin® not only as a neutralizing agent but also as a vector to increase target-specificity or an agent to empower third parties’ molecules. This novel class of targeting ligands called are potent antibody-mimetics, exhibiting high affinity and specificity for capture, targeting and interaction wit biomolecules. Nanofitins® demonstrate many small molecule-like attributes such as a very small size (7 kDa, around 20 times smaller than a monoclonal antibody), an extreme robustness and a better tissue penetration. Deriving from a naturally hyperstable scaffold, Nanofitins® are resistant to temperature and pH, stable to proteases, spontaneously refolding… Nanofitins® are produced by simple, scalable, GMP- compliant bacterial fermentation or by chemical synthesis.
Disease:
Details: * On June 22, 2016, Affilogic announced that the company has signed a collaboration and license agreement with Sanofi forthe development of Nanofitin®-conjugated biotherapeutics. In the framework of a research collaboration initiated in 2012, Affilogic applied its alternative scaffold technology, the Nanofitins®, for a joint discovery and development of
Nanofitins® against an undisclosed target nominated by Sanofi. Affilogic selected Nanofitin® candidates from their proprietary libraries for subsequent conjugation to Sanofi proprietary molecules.
Under this agreement, Affilogic and Sanofi will combine research efforts to establish optimized Nanofitin®-conjugated biotherapeutics and carry out further preclinical development of conjugates. Sanofi has obtained exclusivity on 2 different Nanofitin® families and will have sole responsibility for all clinical development and commercial activities of such Nanofitin®-conjugated biotherapeutics.
Under the terms of the agreement, Affilogic will grant worldwide exclusive rights to all the development projects and is entitled to receive research funding, future milestones payments and royalties for each conjugate. Details on the Nanofitin® target or indications are not disclosed by the partners.
Financial terms:
Latest news:
